eams
MHRA gives OK to Bavencio for first-line maintenance of advanced bladder cancer via the Early Access to Medicines Scheme
September 3, 2020Sales and Marketing Bavencio, MHRA, Merck, Pfizer, UK, eams, pharma
It has been revealed that Bavencio (avelumab), jointly developed by Merck KGaA and Pfizer, has been approved by the UK …
Refining the system: Improving patients’ access to medicine
September 25, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NCIE, drug access, eams, market access, pharma, pharmaceuticals
The MHRA and NICE have been slowly improving the ways that the UK’s patients access medicines, but now Brexit threatens …
MHRA accepts Roche’s Tecentriq into Early Access to Medicines scheme
January 25, 2017Research and Development, Sales and Marketing MHRA, Roche, eams, tecentriq
Roche’s Tecentriq (atezolizumab) has scored another positive opinion, this time from the Medicines and Healthcare products Regulatory Agency (MHRA), which …
UK lung cancer patients get early access to breakthrough BMS drug
February 5, 2016Research and Development, Sales and Marketing Bristol-Myers Squibb, MHRA, NICE, eams, opdivo
UK lung cancer patients are to get access to Bristol Myers-Squibb’s Opdivo (nivolumab) through the Early Access to Medicines Scheme …
Early UK access for AstraZeneca lung cancer drug
December 9, 2015AstraZeneca, Early Access to Medicines Scheme, Tagrissa, eams, lung cancer, non small cell lung cancer, non-small cell lung cancer, osimertinib
UK patients will be among the first in Europe to have free access to AstraZeneca’s cancer drug osimertinib, after the …
Novartis’ new heart failure medicine recommended for EU approval
September 25, 2015Medical Communications, Research and Development Entresto, Novartis, eams, heart failure
The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Novartis’s heart failure medication Entresto …
AstraZeneca lung cancer drug clears UK market access hurdle
September 4, 2015Sales and Marketing AZD9291, AstraZeneca, Early Access to Medicines Scheme, MHRA, NSCLC, eams, lung cancer, non-small cell lung cancer
Follow @Pharmafocus
Novartis heart failure drug available via EAMS
September 3, 2015Sales and Marketing Early Access to Medicines Scheme, Entresto, LCZ696, MHRA, Novartis, eams, heart failure, sacubitril/valsartan
Novartis has won the investigational heart failure treatment LCZ696 (sacubitril valsartan) will be available in the UK under the Early …
Opdivo launched in the UK for skin cancer
July 2, 2015Sales and Marketing BMS, Bristol-Myers Squibb, EMA, Early Access to Medicines Scheme, MHRA, eams, melanoma, opdivo, skin cancer
Bristol-Myers Squibb has launched its cancer immunotherapy treatment Opdivo in the UK for patients with advanced skin cancer. Opdivo (nivolumab) …
BMS’ Opdivo accepted to UK early access scheme
June 30, 2015Sales and Marketing BMS, Cancer, NSCLC, eams, keytruda, opdivo
Bristol-Myers Squibb has scored another first with its new-generation oncology therapy Opdivo, which has become the first lung cancer drug …
NICE sets out office for market access plans
May 28, 2015Sales and Marketing ABPI, EMA, NHS, NICE, eams, market access
The UK healthcare watchdog NICE is to set up a new office for market access to advise pharma companies on …
BMS lifted by new products
April 28, 2015Sales and Marketing BMS, NICE, Q1, eams, immuno-oncology and hepatitis C
New drugs have helped Bristol-Myers Squibb see a slight increase in sales for the first quarter of 2015. Total revenues …
Novartis heart drug steps closer to EAMS scheme
April 23, 2015Sales and Marketing LCZ696, MHRA, Medicines and Healthcare products Regulatory Agency, NICE, eams, pim, sacubitril/valsartan
Novartis’ investigational heart failure drug LCZ696 has been handed a Promising Innovative Medicine designation (PIM) after showing that it significantly …
Novartis in major oncology drive
March 30, 2015Research and Development, Sales and Marketing Cancer, FDA, MHRA, Novartis, aduro, ceritinib, eams, early access, zykadia
Novartis says it is ‘stepping up its efforts’ in cancer by launching major initiatives to discover new treatments to combat …
Merck’s cancer drug sees first ever early access nod
March 11, 2015Sales and Marketing Cancer, ICR, Merck, eams, early access, keytruda, melanoma, oncology, pembrolizumab
Merck’s skin cancer drug Keytruda has become the first drug to be approved through the new Early Access to Medicines …
